PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement...

PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime
Achievement Award From Good Clinical Practice Journal

BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- PAREXEL International
Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services
provider, today announced that Alberto Grignolo, Ph.D., Corporate Vice
President, PAREXEL Consulting, has received a Lifetime Achievement Award from
the Good Clinical Practice Journal (GCPj). Dr. Grignolo was honored at the
GCPj Awards ceremony, recognizing excellence in clinical research, which was
held October 22, 2008 at the Banqueting House in London, England.
According to Helena Jensen, Publisher of the Good Clinical Practice
Journal, "GCPj's Lifetime Achievement Award is presented to an exceptional
individual with a distinguished career in the field of clinical development.
We are pleased to honor Dr. Grignolo, who exemplifies dedication to advancing
critical aspects of our industry, and whose achievements are especially
notable for being consistently forward looking and visionary, from the
championing of personalized medicine to his current role on the Executive
Committee of the Clinical Trials Transformation Initiative."
"This honor from the GCPj readership and global clinical development
community is for me not an end but rather a new beginning. This recognition is
a challenge to inspire others to pursue our shared mission to prevent and cure
disease, while continuing to improve the clinical trial enterprise and
worldwide standards and practices to benefit patients. Together, through the
important work that we do, we can promote innovation, help make personalized
therapy a reality in our lifetime, meet urgent medical needs, insist on
integrity and ethical behavior, and improve patient access to treatments,"
said Dr. Grignolo.
With more than 26 years of experience in regulatory and development
strategy, Dr. Alberto Grignolo has helped numerous companies manage business
risk by promoting effective regulatory strategies and relationships with
regulators. Leading a global team of experts at PAREXEL Consulting, Dr.
Grignolo oversees the management of regulatory submissions for clients with
Regulatory Authorities worldwide. Dr. Grignolo has been an advocate for
progress in personalized drug development, and has helped the industry
recognize emerging opportunities to deliver safe and effective medicines to
the right patients. Prior to joining PAREXEL, Dr. Grignolo served as President
of FIDIA Pharmaceutical Corporation, and held management positions in
regulatory affairs at Smith Kline & French Laboratories. He has served as an
adviser to the Institute of Medicine of the National Academy of Sciences on
human subject protection in clinical trials. He is currently a member of the
Executive Committee of the Clinical Trials Transformation Initiative (CTTI).
Dr. Grignolo has served as a leader of several industry organizations,
including as Chairman of RAPS and on the Board of Directors for DIA. Dr.
Grignolo holds a Ph.D. in Psychology from the University of North Carolina at
Chapel Hill and a B.S. degree from Duke University. He completed postdoctoral
work in neuropharmacology at Duke University Medical Center. He is currently
Adjunct Associate Professor at the Massachusetts College of Pharmacy and
Health Sciences.
Good Clinical Practice Journal (GCPj) (www.gcpj.com) addresses the
regulatory, strategic, and clinical issues that directly impact clinical
studies globally.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based contract
research, medical communications and consulting services to the worldwide
pharmaceutical, biotechnology and medical device industries. Committed to
providing solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development and
commercialization continuum, from drug development and regulatory consulting
to clinical pharmacology, clinical trials management, medical education and
reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides
advanced technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston, Massachusetts,
PAREXEL operates in 69 locations throughout 52 countries around the world, and
has approximately 8,800 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future
results and events. For this purpose, any statements contained herein that are
not statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "intends," "appears," "estimates," "projects," "targets," and
similar expressions are also intended to identify forward-looking statements.
The forward-looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ significantly
from the results discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference include, but are
not limited to, risks associated with: actual operating performance; actual
expense savings and other operating improvements resulting from recent
restructurings; the loss, modification, or delay of contracts which would,
among other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries and
clients; the Company's ability to win new business, manage growth and costs,
and attract and retain employees; the Company's ability to complete additional
acquisitions and to integrate newly acquired businesses or enter into new
lines of business, including ClinPhone; the impact on the Company's business
of government regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse impact of health
care reform; and the effects of exchange rate fluctuations and other
international economic, political, and other risks. Such factors and others
are discussed more fully in the section entitled "Risk Factors" of the
Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008
as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is
incorporated by reference in this press release. The forward-looking
statements included in this press release represent the Company's estimates as
of the date of this release. The Company specifically disclaims any obligation
to update these forward-looking statements in the future. These forward-
looking statements should not be relied upon as representing the Company's
estimates or views as of any date subsequent to the date of this press
release.
PAREXEL is a registered trademark of PAREXEL International Corporation,
and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All
other names or marks may be registered trademarks or trademarks of PAREXEL
International Corporation, Perceptive Informatics, Inc. or their respective
owners and are hereby acknowledged.

Contacts:
Jennifer Baird, Senior Director of Rebecca Passo
Public Relations
PAREXEL International SHIFT Communications
Tel: +781-434-4409 Tel: +617-779-1817
Email: Jennifer.Baird@PAREXEL.com Email: rpasso@shiftcomm.com

SOURCE PAREXEL International Corporation

Jennifer Baird, Senior Director of Public Relations of PAREXEL International,
+1-781-434-4409, Jennifer.Baird@PAREXEL.com, or Rebecca Passo of SHIFT
Communications, +1-617-779-1817, rpasso@shiftcomm.com